ClinicalTrials.gg
CompletedNCT00844376Updated Mar 10, 2021Results posted

Bioavailability Study for New Atorvastatin Formulation

A Phase 4 interventional study of Atorvastatin suspension and Lipitor in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
72nd of 75
12 · median 148
Started
2008
with 12 others
Phase 4
28 of 77
1 open now
Registered
34th of 77
by date
Lead sponsor
10 of 77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 72nd largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 28 in phase 4, and was the 34th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.

Read the detailed description

Estimation of Relative Bioavailability

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects
  • (BMI) of approximately 18 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • A positive urine drug screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Other
    Test

    Extemporaneous preparation suspension Atorvastatin prototype formulation

    Drug: Atorvastatin suspension

  • Other
    Reference

    Commercial atorvastatin tablet (Lipitor®)

    Drug: Lipitor

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48)

    Geometric means of AUC48 = area under the plasma concentration-time profile from time zero (0) to 48 hours postdose of atorvastatin (test versus \[vs\] reference); measured in nanograms times hour per milliliter (ng.hr/mL).

    Time frame: 5 days

  2. Area Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity)

    Geometric means of AUC infinity (AUCinf) = area under the plasma concentration-time curve from time zero (0) extrapolated to infinite time; measured in ng.hr/mL of atorvastatin (test vs reference).

    Time frame: 5 days

  3. Maximum Observed Plasma Concentration (Cmax)

    Geometric mean of Cmax = maximum observed plasma concentration of atorvastatin (test vs reference); measured in nanograms per milliliter (ng/mL).

    Time frame: 5 days

Secondary outcomes

  1. Area Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast)

    Geometric mean of AUClast = area under the plasma concentration-time curve from time zero (0) to the last measurable concentration of atorvastatin (test vs reference); measured as ng.hr/mL

    Time frame: 5 days

  2. Terminal Phase Rate Constant (Kel)

    Geometric mean of Kel= termination phase rate constant for atorvastatin (test vs reference); measured as 1 per hour (1/hr).

    Time frame: 5 days

  3. Time to Reach Maximum Plasma Concentration (Tmax)

    Median of Tmax = time to maximum plasma concentration (Cmax) (test vs reference); measured in hours (hr).

    Time frame: 5 days

  4. Plasma Elimination Half-life (t1/2)

    Mean of t1/2 = terminal elimination half-life of atorvastatin (test vs reference); measured in hours.

    Time frame: 5 days

07

Results

Posted Oct 21, 2009

Participant flow

One center in the U.S.

Period 1: First Intervention
Participant flow — Period 1: First Intervention
MilestoneTest Drug First (Atorvastatin EP Suspension)Reference Drug First (Atorvastatin Tablet)
Started66
Completed56
Not completed10
Withdrew: Withdrawal by subject10
Period 2: Second Intervention
Participant flow — Period 2: Second Intervention
MilestoneTest Drug First (Atorvastatin EP Suspension)Reference Drug First (Atorvastatin Tablet)
Started56
Completed56
Not completed00

Outcome measures

PrimaryArea Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48)

Geometric means of AUC48 = area under the plasma concentration-time profile from time zero (0) to 48 hours postdose of atorvastatin (test versus \[vs\] reference); measured in nanograms times hour per milliliter (ng.hr/mL).

Time frame:
5 days
Reported as:
Geometric mean · ng.h/mL
Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48)
ng.h/mLTestReference
Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48)135.05 (52.5 to 233.00)140.79 (64.10 to 243.00)
Statistical analysis
  • Test vs Reference · Mixed Models Analysis · Ratio of adjusted geometric means: 95.77 · 90% CI 85.82 to 106.88Natural log transformed AUC48 was analyzed using a mixed effect model with sequence, period and treatment as a fixed effect and subject within sequence as a random effect.
PrimaryArea Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity)

Geometric means of AUC infinity (AUCinf) = area under the plasma concentration-time curve from time zero (0) extrapolated to infinite time; measured in ng.hr/mL of atorvastatin (test vs reference).

Time frame:
5 days
Reported as:
Geometric mean · ng.hr/mL
Area Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity)
ng.hr/mLTestReference
Area Under the Curve From Predose (Time Zero) to Extrapolated Infinite Time (AUC Infinity)135.88 (51.20 to 234.00)142.86 (65.00 to 247.00)
Statistical analysis
  • Test vs Reference · Mixed Models Analysis · Ratio of adjusted geometric means: 95.04 · 90% CI 84.99 to 106.27Natural log transformed AUCinf was analyzed using a mixed effect model with sequence, period and treatment as a fixed effect and subject within sequence as a random effect.
SecondaryArea Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast)

Geometric mean of AUClast = area under the plasma concentration-time curve from time zero (0) to the last measurable concentration of atorvastatin (test vs reference); measured as ng.hr/mL

Time frame:
5 days
Reported as:
Geometric mean · ng.hr/mL
Area Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast)
ng.hr/mLTestReference
Area Under the Curve From Predose (Time Zero) to Last Quantifiable Concentration (AUClast)130.21 (45.50 to 231.00)137.49 (56.00 to 243.00)
Statistical analysis
  • Test vs Reference · Mixed Models Analysis · Ratio of adjusted geometric means: 94.86 · 90% CI 83.86 to 107.29Natural log transformed AUClast was analyzed using a mixed effect model with sequence, period and treatment as a fixed effect and subject within sequence as a random effect.
PrimaryMaximum Observed Plasma Concentration (Cmax)

Geometric mean of Cmax = maximum observed plasma concentration of atorvastatin (test vs reference); measured in nanograms per milliliter (ng/mL).

Time frame:
5 days
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLTestReference
Maximum Observed Plasma Concentration (Cmax)38.74 (20.30 to 86.80)33.24 (16.60 to 52.20)
Statistical analysis
  • Test vs Reference · Mixed Models Analysis · Ratio of adjusted geometric means: 117.90 · 90% CI 98.22 to 141.53Natural log transformed Cmax was analyzed using a mixed effect model with sequence, period and treatment as a fixed effect and subject within sequence as a random effect.
SecondaryTerminal Phase Rate Constant (Kel)

Geometric mean of Kel= termination phase rate constant for atorvastatin (test vs reference); measured as 1 per hour (1/hr).

Time frame:
5 days
Reported as:
Geometric mean · 1/hr
Terminal Phase Rate Constant (Kel)
1/hrTestReference
Terminal Phase Rate Constant (Kel)0.12 (0.09 to 0.26)0.10 (0.06 to 0.15)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax)

Median of Tmax = time to maximum plasma concentration (Cmax) (test vs reference); measured in hours (hr).

Time frame:
5 days
Reported as:
Median · hr
Time to Reach Maximum Plasma Concentration (Tmax)
hrTestReference
Time to Reach Maximum Plasma Concentration (Tmax)0.52 (0.50 to 2.00)0.50 (0.50 to 3.00)
SecondaryPlasma Elimination Half-life (t1/2)

Mean of t1/2 = terminal elimination half-life of atorvastatin (test vs reference); measured in hours.

Time frame:
5 days
Reported as:
Mean · hr
Plasma Elimination Half-life (t1/2)
hrTestReference
Plasma Elimination Half-life (t1/2)5.95 ± 1.407.21 ± 2.23

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test—0/12 (0%)1/12 (8.3%)
Reference—0/11 (0%)1/11 (9.1%)
Most frequent other events
Most frequent other events
EventTestReference
headacheNervous system disorders1/121/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean34.8 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female0
Male12
08

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2009
First posted
Feb 16, 2009
Start
Feb 2008
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Oct 21, 2009
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00844376
Responsible party
Sponsor
First posted
Feb 16, 2009
Start date
Feb 2008
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Oct 21, 2009
Last update
Mar 10, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion